GEN Exclusives

More »

GEN News Highlights

More »
May 23, 2012

XDx, LabCorp to Develop Lupus Flare Predictor Test

  • XDx and Laboratory Corporation of America® (LabCorp) are joining forces to discover markers for systemic lupus erythematosus (SLE). Under the collaboration and license agreement, each party will take part in the discovery, while LabCorp will develop and commercialize a diagnostic test to predict SLE flares.

    The deal combines XDx’ autoimmune diagnostics research and discovery experience and SLE blood sample database with LabCorp’s diagnostic development and commercialization resources. “We have developed an extensive database of lupus blood samples that we will use in collaboration with LabCorp to initiate its development of a biomarker for the flare test,” says Pierre Cassigneul, XDx’ president and CEO.

    “Building upon our success in the immune-mediated diagnostic market with our first approved product, AlloMap® Molecular Expression Testing, XDx is dedicated to expanding its pipeline of high-value diagnostic tests to other diseases that involve the activity of the immune system,” Cassigneul adds.

    XDx’ AlloMap Molecular Expression Testing is FDA-cleared. It provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for postcardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »